CAPR Falls 7.6% After Shareholder Class Action Alert
Capricor Therapeutics (CAPR) fell 7.6% on Aug 21, 2026 after a shareholder alert highlighted a lead-plaintiff deadline tied to a securities class action.
What Capricor Therapeutics announced
The news was a shareholder alert circulated by ClaimsFiler, reminding investors of a lead plaintiff deadline in a class action lawsuit against Capricor Therapeutics. The alert said the case covers investors who purchased Capricor securities between December 17, 2025 and July 26, 2026 (the “Class Period”). The lawsuit is pending in the United States District Court for the Southern District of California.
According to the alert, Capricor and certain executives are accused of failing to disclose material information during the Class Period, allegedly violating federal securities laws. The alert also points to FDA briefing documents published pre-market on July 27, 2026 ahead of a July 29 advisory committee meeting reviewing the Biologics License Application for Deramiocel. Those briefing documents cited changes to the pre-specified statistical analysis plan and stated the final version “was not submitted to FDA for review prior to BLA submission and was not discussed and consequently not agreed upon,” with the final plan finalized one day before the data was unblinded.
What it means for Capricor Therapeutics
A shareholder alert like this can refocus attention on legal overhang and process questions raised in the FDA review materials referenced in the lawsuit narrative. While the alert itself doesn’t change the underlying facts, it can amplify scrutiny by highlighting deadlines and the scope of the claims.
For Capricor, the situation underscores how regulatory communications and trial-analysis documentation can become central issues in investor litigation. It also means headlines may continue to track both the legal process and any developments related to the FDA’s review of the Deramiocel BLA.
How the stock reacted
CAPR sold off early and finished lower on the day.
| Window | Move |
|---|---|
| 5 min | -7.2% |
| 10 min | -1.0% |
| 30 min | +0.6% |
| 1 hour | +1.8% |
| end of day | -7.6% |
On a market-adjusted basis, the stock’s same-day move was -7.6% versus SPY.